Tranilast
Tranilast
Tranilast
| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-2234-10MG | Tranilast | 10mg | $84.00 | |
| GBM-2234-50MG | Tranilast | 50mg | $336.00 |
-
Description
NFkB inhibitor
-
Specifications
Bioassays Specification Bio-Activity NFkB inhibitor Chemical Name N-(3’,4’-Dimethoxycinnamoyl)anthranilic acid Function / Pharmacology Tranilast is an anti-allergy agent (inhibition of mast cell degranulation) that has been shown to have potent immunomodulatory effects (via inhibition of endotoxin induced: PGE2, IC50 = 1-20 µM; TXB2, IC50 = 10-50 µM; TGFβ1, IC50 = 100-200 µM; IL-8, IC50 = 100 µM) .1,2,3 Tranilast also displays anti-angiogenic properties.4,5 CAS# 53902-12-8 MW 327.34 Molecular Formula C18H17NO5 Solubility Soluble in DMSO (up to 30 mg/ml). Supplied powder Storage as supplied RT Ship temp Ambient References 1) Capper et al., (2000) Modulation of human monocyte activities by tranilast, SB252218, a compound demonstrating efficacy in restenosis; J.Pharmacol.Exp.Ther. 38 2673 / 2) Ward et al., (2002) Tranilast prevents activation of transforming growth factor-b system, leukocyte accumulation and neointimal growth in porcine coronary arteries after stenting Arterioscler.Thromb.Vasc.Biol. 22 940 / 3) Chikaraishi et al. (2001) Tranilast inhibits linterleukin-1b-induced monocyte chemoattractant protein-1 expression in rat mesangial cells; Eur.J.Pharmacol.. 427 151 / 4) Isaji et al. (1997) Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo Br.J.Pharmacol. 122 1061 / 5) Koyama et al. (1999) Tranilast inhibits protein kinase C-dependent signaling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells Br.J.Pharmacol. 127 537 Antibody Specification Alternate Names Rizaben Protein Specification Purity >98% - Reviews
| Bioassays Specification | |
| Bio-Activity | NFkB inhibitor |
| Chemical Name | N-(3’,4’-Dimethoxycinnamoyl)anthranilic acid |
| Function / Pharmacology | Tranilast is an anti-allergy agent (inhibition of mast cell degranulation) that has been shown to have potent immunomodulatory effects (via inhibition of endotoxin induced: PGE2, IC50 = 1-20 µM; TXB2, IC50 = 10-50 µM; TGFβ1, IC50 = 100-200 µM; IL-8, IC50 = 100 µM) .1,2,3 Tranilast also displays anti-angiogenic properties.4,5 |
| CAS# | 53902-12-8 |
| MW | 327.34 |
| Molecular Formula | C18H17NO5 |
| Solubility | Soluble in DMSO (up to 30 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Capper et al., (2000) Modulation of human monocyte activities by tranilast, SB252218, a compound demonstrating efficacy in restenosis; J.Pharmacol.Exp.Ther. 38 2673 / 2) Ward et al., (2002) Tranilast prevents activation of transforming growth factor-b system, leukocyte accumulation and neointimal growth in porcine coronary arteries after stenting Arterioscler.Thromb.Vasc.Biol. 22 940 / 3) Chikaraishi et al. (2001) Tranilast inhibits linterleukin-1b-induced monocyte chemoattractant protein-1 expression in rat mesangial cells; Eur.J.Pharmacol.. 427 151 / 4) Isaji et al. (1997) Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo Br.J.Pharmacol. 122 1061 / 5) Koyama et al. (1999) Tranilast inhibits protein kinase C-dependent signaling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells Br.J.Pharmacol. 127 537 |
| Antibody Specification | |
| Alternate Names | Rizaben |
| Protein Specification | |
| Purity | >98% |